NPR just aired a short story about a young woman who experienced postpartum psychosis after the birth of her first child. Â It was a short article but it brought up several important themes. The [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). Â SAGE-547, now called brexanolone, is a neurosteroid, an analogue of allopregnanolone and an allosteric modulator of [...]
Earlier this year the American College of Obstetricians and Gynecologists (ACOG) released a revised Committee Opinion calling for a new paradigm for postpartum care in the United States. Â Moving away from the single postpartum check [...]
We have long known that postpartum depression may have negative effects on the child and may contribute to deficits in social development and emotional regulation. Exactly what mediates these effects is not so clear; however, [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). Â SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. Â Since that time, Sage Therapeutics [...]
In a recent study from Quebec, researchers compared the risk of postpartum depression in more than 35,000 pregnant women with asthma and almost 200,000 women without asthma. Â They found that rates of postpartum depressive symptoms [...]
In a recent meta-analysis, researchers screened electronic databases and analyzed data from randomized controlled trials (RCTs) of acupuncture for the treatment of postpartum depression (PPD). Primary outcomes included improvement in depressive symptoms, as by scores [...]
Postpartum psychosis (PPP) is a serious condition, occurring in 1 to 2 per 1000 women in the weeks after delivery and associated with extreme delirium-like behavior, delusions, hallucinations, and an increased risk of suicide and [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD). Â SAGE-547, now called brexanolone, is an allosteric modulator of GABA-A receptors. Â We saw the preliminary [...]
In the United States, about one out of every 160 pregnancies ends in stillbirth, defined as a pregnancy loss occurring after 20 weeks' gestation. Â Perinatal loss is a traumatic event for women and their families. [...]
